News | April 03, 2026
ZEISS India strengthens portfolio with the launch of ZEISS ClearMind lenses
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
A key milestone in this journey has been the introduction of TREAT Program, a first-of-its-kind clinical initiative introduced in India
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
This makes VLCC the sole institution in the country authorised to conduct in-person NCLC exams
Subscribe To Our Newsletter & Stay Updated
